Publikasjoner
Vitenskapelig artikkel
- Marte Karen Brattås; Kimberley Joanne Hatfield; Kristin Paulsen Rye et al. (2026). Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors. (ekstern lenke)
- Marte Karen Brattås; Franziska Stilla Maria Görtler; Silje Johansen et al. (2025). Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors. (ekstern lenke)
- Marte Karen Brattås; Anette Lodvir Hemsing; Kristin Paulsen Rye et al. (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. (ekstern lenke)
- Marte Karen Brattås; Håkon Reikvam (2017). Ringsideroblaster. (ekstern lenke)
- Marte Karen Brattås; Håkon Reikvam; Tor Henrik Anderson Tvedt et al. (2019). Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. (ekstern lenke)
- Marte Karen Brattås; Håkon Reikvam; Tor Henrik Anderson Tvedt et al. (2019). Dasatinib is an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. (ekstern lenke)
- Sissel Dyrstad; Kimberley Joanne Hatfield; Endre Stigen et al. (2025). Mapping of Functional Metabolic Phenotypes in Acute Myeloid Leukemia. (ekstern lenke)
- Marte Karen Brattås; Kyrre Flattun Lilleeng; Randi Hovland et al. (2018). Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. (ekstern lenke)
Doktorgradsavhandling
Vitenskapelig litteraturgjennomgang
- Marte Karen Brattås; Håkon Reikvam; Tor Henrik Anderson Tvedt et al. (2019). Precision medicine for TP53-mutated acute myeloid leukemia. (ekstern lenke)
- Sushma Bartaula-Brevik; Marte Karen Brattås; Tor Henrik Anderson Tvedt et al. (2018). Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. (ekstern lenke)